Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.78 USD -1.44% Intraday chart for Novavax, Inc. -1.04% -0.42%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novavax Reports Settlement Agreement With Fujifilm MT
Wall St ends higher as Fed sees three rate cuts RE
Wall St advances as US Fed keeps three rate cuts on the horizon RE
Novavax: NACI gives the green light for Covid vaccine in Canada CF
India's Serum looks beyond COVID with new vaccines for malaria, dengue RE
HC Wainwright Cuts Price Target on Novavax to $19 From $35, Keeps Buy Rating MT
Novavax Q4 Loss Narrows, Revenue Declines -- Shares Fall MT
Wall Street set for lower open in run-up to inflation data RE
Transcript : Novavax, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024 CI
Novavax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (NVAX) NOVAVAX Posts Q4 Revenue $291.3M, vs. Street Est of $322M MT
Novavax sees 2024 sales flat to lower, aims to pick up COVID vaccine market share RE
Novavax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
B. Riley Trims Novavax's PT to $11 From $12 After Reaching Settlement on Gavi Arbitration Dispute, Keeps Buy Rating MT
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care Stocks Rise Thursday Afternoon MT
Top Stories at Midday: Weekly Jobless Claims Drop; Nvidia Continues to Rise; AT&T Cellular Outage; Novavax Settles Vaccine Dispute; Synopsys Rises on 2024 Guidance MT
Novavax Reaches Settlement With Vaccine Alliance; Shares Rise MT
Navavax: agreement with Gavi puts an end to ongoing arbitration CF
US, Canadian companies kick off 2024 with layoffs RE
US, Canadian companies kick off 2024 with layoffs RE
Job cuts spill beyond tech sector RE
UK Regulator Approves Pfizer–BioNTech’s COVID-19 Vaccine License Change MT
Second malaria vaccine highly protective, trial results show RE
Chart Novavax, Inc.
More charts
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.78 USD
Average target price
15.4 USD
Spread / Average Target
+222.18%
Consensus
  1. Stock
  2. Equities
  3. Stock Novavax, Inc. - Nasdaq
  4. News Novavax, Inc.
  5. Novavax Reports Widened Q3 Loss on Higher Revenue; Plans to File for FDA EUA for COVID-19 Vaccine by Year's End